CTRI/2023/01/049263
Not yet recruiting
Phase 2
Phase II Clinical Study to Evaluate Efficacy of Darvyadi Rasakriya In Sthula Pramehi on the Basis Of Ayurvedic Parameters with reference to Newly Diagnosed Type II Diabetes Mellitus
Aushadhi Bhavan0 sites0 target enrollmentTBD
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Aushadhi Bhavan
- Status
- Not yet recruiting
- Last Updated
- 3 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Newly diagnosed T2DM with any symptom of Polyuria, Polydipsia, Polyphagia, Bodyache, Giddiness, Polyneuritis, Fatigue and other symptoms mentioned in ayurvedic text
- •HbA1c 6\.5 to 8\.5
- •BMI More than 23
- •Subjects not taking any OHA
- •Subjects diagnosed within 2 years back
- •Subjects who agree to participate in the study and submit a written informed consent form
Exclusion Criteria
- •Known Cases of type I DM
- •Patients of gestational diabetes
- •Any unstable Heart disease
- •Pregnant / Lactating women.
- •Alcoholics and/or drug abusers
- •Patients with evidence of malignancy
- •Patients suffering from major systemic illness necessitating long term drug treatment (Rheumatoid arthritis, Psycho\-Neuro, endocrinal disorders, etc.)
- •Patients who have completed participation in any other clinical trial during the past one (01\) month.
- •Any other condition which the Investigator thinks may jeopardize the study
Outcomes
Primary Outcomes
Not specified
Similar Trials
Unknown
Phase 2
Phase 2 study of DS-8500aType 2 Diabetes MellitusJPRN-jRCT2080222546DAIICHISANKYO Co.,Ltd.90
Active, not recruiting
Not Applicable
A phase II clinical trial on the combination of dabrafenib and trametinib for BRAF-inhibitor pretreated patients with advanced BRAF V600 mutant melanomaadvanced BRAF V600 mutant melanomaMedDRA version: 16.1Level: PTClassification code 10025671Term: Malignant melanoma stage IVSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 16.1Level: PTClassification code 10025670Term: Malignant melanoma stage IIISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 16.1Level: HLTClassification code 10027156Term: Skin melanomas (excl ocular)System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 16.1Level: PTClassification code 10066600Term: Melanoma recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 16.1Level: PTClassification code 10027480Term: Metastatic malignant melanomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2013-004966-33-BEZ Brussel
Not yet recruiting
Phase 2
Efficacy of Unani Formulation in White PatchesHealth Condition 1: L80- VitiligoCTRI/2022/04/041571Rajiv Gandhi University Of Health Sciences
Not yet recruiting
Not Applicable
Daratumumab plus DCEP for MM with plasmacytomaKCT0003345Seoul National University Hospital33
Recruiting
Not Applicable
A clinical study to investigate the efficacy of diuretics to the HF patients with proteinuria and edema.Heart FailureJPRN-UMIN000006212Social Insurance Yokohama Central Hospital15